Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
Saved in:
Main Authors: | Alice Tzeng, Tony H Tzeng, Moshe C Ornstein |
---|---|
Format: | article |
Language: | EN |
Published: |
BMJ Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/dae64e52781b44a2a1ebf06a7cb4e9d9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Xiuqiong Chen, et al.
Published: (2021) -
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
by: Tian Zhang, et al.
Published: (2021) -
Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
by: Guang‐Li Zhu, et al.
Published: (2021) -
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
by: Yeon Jeong Kim, et al.
Published: (2021) -
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
by: Xiaozhun Huang, et al.
Published: (2021)